Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 10/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067256 | 0.84 | MEN1 (0.56) | CDK4CCND1PARP1KDM4EALDH1A1 | |
| SCHEMBL10067291 | 0.84 | PTGS2 (0.44) | PTGESJAK2CDK4CCND1PARP1 | |
| SCHEMBL10067268 | 0.83 | ESR1 (0.50) | PTGESJAK2CDK4CCND1PARP1 | |
| SCHEMBL10082885 | 0.82 | RHEB (0.37) | PTGESJAK2CDK4CCND1GABRA1 | |
| SCHEMBL10067270 | 0.81 | MAPK14 (0.50) | PTGESJAK2CDK4CCND1PARP1 | |
| SCHEMBL10067290 | 0.81 | CDK4 (0.41) | PTGESJAK2CDK4CCND1PARP1 | |
| SCHEMBL10067305 | 0.81 | CDK4 (0.41) | PTGESJAK2CDK4CCND1PARP1 | |
| SCHEMBL10067301 | 0.81 | PTGES (0.38) | PTGESJAK2CDK4CCND1KDM4E | |
| SCHEMBL17368965 | 0.80 | PARP1 (0.42) | PTGESJAK2CDK4CCND1PARP1 | |
| SCHEMBL10067258 | 0.79 | MAPK14 (0.54) | PTGESJAK2CDK4CCND1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692113-B1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| WO-2010102393-A1 | 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS | LORUS THERAPEUTICS INC. (CA) | 2010-09-16 | — | — | WO | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| WO-2005047266-A9 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | PTGES 2604/4885JAK2 406/4885CDK4 63/4885 |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | AHR, CBR3, AADAC | PTGES 2602/4885JAK2 407/4885CDK4 61/4885 |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | PTGES 2604/4885JAK2 406/4885CDK4 63/4885 |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | PTGES 1934/4885JAK2 759/4885CDK4 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.